Invasive fungal infections in a pediatric hematology-oncology department: A 16-year retrospective study

Document Type : Original Articles

Authors

1 Hematology-Oncology Unit, 2nd Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

2 First Department of Microbiology, School of Medicine, Aristotle University of Thessaloniki, Greece

Abstract

Background and Purpose: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in immunocompromised children. The purpose of our study was to evaluate the incidence of IFIs in pediatric patients with underlying hematologic malignancies and determine the patient characteristics, predisposing factors, diagnosis, treatment efficacy, and outcome of IFIs.
Materials and Methods: For the purpose of the study, a retrospective analysis was performed on cases with proven and probable fungal infections from January 2001 to December 2016 (16 years).
Results: During this period, 297 children with hematologic malignancies were admitted to the 2nd Pediatric Department of Aristotle University of Thessaloniki, Greece, and 24 cases of IFIs were registered. The most common underlying diseases were acute lymphoblastic leukemia (ALL; n=19, 79%), followed by acute myeloid leukemia (AML; n=4, 17%) and non-Hodgkin lymphoma (NHL; n=1, 4%). The crude incidence rates of IFIs in ALL, AML, and NHL were 10.5%, 18.2%, and 2.8% respectively. Based on the results, 25% (n=6) and 75% (n=18) of the patients were diagnosed as proven and probable IFI cases, respectively. The lung was the most common site of involvement in 16 (66.7%) cases. Furthermore, Aspergillus and Candida species represented 58.3% and 29.1% of the identified species, respectively. Regarding antifungal treatment, liposomal amphotericin B was the most commonly prescribed therapeutic agent (n=21), followed by voriconazole (n=9), caspofungin (n=3), posaconazole (n=3), micafungin (n=1), and fluconazole (n=1). In addition, 12 children received combined antifungal treatment. The crude mortality rate was obtained as 33.3%. Conclusion: As the findings of the present study indicated, despite the progress in the diagnosis and treatment of IFIs with the use of new antifungal agents, the mortality rate of these infections still remains high.
 

Keywords

References

1. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infection in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006; 91(8):1068-75.
2. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011; 3:175-91.
3. Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of invasive fungal disease in children. J Pediatric
Infect Dis Soc. 2017; 6(Suppl 1):S3-11.
4. Tragiannidis A, Tsoulas C, Kerl K, Groll AH. Invasive candidiasis: update on current pharmacotherapy options and future perspectives. Expert Opin Pharmacother. 2013; 14(11):1515-28.
5. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993; 167(5):1247-51.
6. Edmont MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis. 1999; 29(2):239-44.
7. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol. 2002; 81(5):233-43.
8. Tragiannidis A, Fegeler W, Rellensmann G, Debus V, Müller V, Hoernig-Franz I, et al. Candidaemia in a European pediatric university hospital: a 10-year observational study. Clin Microbiol Infect. 2012; 18(2):E27-30.
9. Athanassiadou F, Tragiannidis A, Kourti M, Papageorgiou T, Velegraki A, Drevelengas A. Invasive fungal infections in children with hematological malignancies: a 5-year study. Pediatr Hematol Oncol. 2006; 23(2):163-6.
10. Tragiannidis A, Roilides E, Walsh TJ, Groll AH. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis. 2012; 54(2):258-67.
11. Bartlett AW, Cann MP, Yeoh DK, Bernard A, Ryan AL, Blyth CC, et al. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10‐year review. Pediatr Blood Cancer. 2019; 66(4):e27564.
12. Wang SS, Kotecha RS, Bernard A, Blyth CC, McMullan BJ, Cann MP, et al. Invasive fungal infections in children with acute lymphoblastic leukaemia: results from four Australian centers, 2003‐2013. Pediatr Blood Cancer. 2019; 66(10):e27915.
13. Sahbudak Bal Z, Yilmaz Karapinar D, Karadas N, Sen S, Onder Sivis Z, Akinci AB, et al. Proven and probable invasive fungal infections in children with acute lymphoblastic leukaemia: results from an university hospital, 2005-2013. Mycoses. 2015; 58(4):225-32.
14. Yeh TC, Liu HC, Wang LY, Chen SH, Liang DC. Invasive fungal infection in children undergoing chemotherapy for cancer. Ann Trop Paediatr. 2007; 27(2):141-7.
15. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014; 15(8):e327-40.
16. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012; 18(Suppl 7):38-52.
17. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al; Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46(12):1813-21.
18. Kumar J, Singh A, Seth R, Xess I, Jana M, Kabra SK. Prevalence and predictors of invasive fungal infections in children with persistent febrile neutropenia treated for acute leukemia – a prospective study. Indian J Pediatr. 2018; 85(12):1090-5.
19. Villarroel M, Avilés CL, Silva P, Guzmán AM, Poggi H, Alvarez AM, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation. Pediatr Infect Dis J. 2010; 29(9):816-21.
20. Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer. 2011; 56(7):1092-7.
21. Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007; 48(1):28-34.
22. Otto WR, Green AM. Fungal infections in children with haematologic malignancies and stem cell transplant recipients. Br J Haematol. 2020; 189(4):607-24.
23. Downes KJ, Fisher BT, Zane NR. Administration and dosing of systemic antifungal agents in pediatric patients. Paediatr Drugs. 2020; 22(2):165-88.
24. Iosifidis E, Papachristou S, Roilides E. Advances in the treatment of mycoses in pediatric patients. J Fungi (Basel). 2018; 4(4): E115. 
Current Medical Mycology
Volume 6, Issue 2
June 2020
Pages 37-42

Files

Share

How to cite

Statistics